A 2025 meta-analysis of 3,892 implants found higher 5-year survival in patients over 75 (96.8%) than in patients aged 65 to 75 (92.1%). Age itself isn’t the disqualifier most people assume it is.

Patients often self-screen out of All-on-4 based on age or a vague sense they don’t have “enough bone,” without knowing what the actual data shows. This guide covers age, bone density, medication risk, other health factors, and the alternative pathway when bone volume genuinely is insufficient.

Key Takeaways

  • Age alone doesn’t disqualify anyone, a 2025 meta-analysis found higher 5-year survival in patients over 75 (96.8%) than in the 65-75 group (92.1%).
  • Standard osteoporosis medication is not a contraindication, MRONJ risk is roughly 100 to 1,000 times higher with cancer-dose IV bisphosphonates than oral osteoporosis dosing.
  • If bone volume is insufficient, zygomatic implants offer a well-documented alternative with 96.2% six-year survival.
Elderly man wearing eyeglasses sitting in a dental chair, examining his teeth with a mirror during a dental appointment

Is There an Age Limit for All-on-4?

No sourced upper age limit exists in the literature. A 7-year comparative study of patients aged 45 to 60 versus 75 and older found implant failure rates of 1.52% and 0.76% respectively, not a statistically significant difference, and peri-implantitis was actually higher in the younger group (PMC10342767, Journal of Clinical Medicine, 2023).

A larger 2025 meta-analysis of 27 studies and 3,892 implants found 5-year survival of 96.8% in patients over 75 versus 92.1% in the 65-75 group, a statistically significant difference favoring the older cohort (PMC12423580, Clinical Oral Implants Research, 2025).

Implant Survival by Age Group Bar chart. Patients over 75 years: 96.8 percent 5-year implant survival. Patients 65 to 75 years: 92.1 percent. Source: PMC12423580, Clinical Oral Implants Research, 2025, meta-analysis of 27 studies and 3,892 implants, p equals 0.031. 96.8% Age 75+ 92.1% Age 65-75 Source: PMC12423580, 2025 (27 studies, 3,892 implants, p=0.031)
Older patients showed higher, not lower, 5-year implant survival in this meta-analysis (PMC12423580, 2025).

Systemic health and healing capacity, not chronological age, determine candidacy. Isn’t that a more useful way to think about it than a birthday-based cutoff?

What Does Bone Density Actually Determine?

Bone density, assessed via CBCT scan, determines achievable insertion torque, generally targeting 25 to 45 Ncm, with values below 20 Ncm signaling elevated failure risk. Denser anterior bone is typically preferred for immediate-loading protocols over the softer posterior bone common in the upper jaw.

Worth being honest here: no study was found quantifying primary-stability differences specifically for placing multiple implants across mixed-density zones simultaneously, as opposed to a single implant. This is a genuine evidence gap, consistent with a similar gap already noted on the pillar page for this cluster.

For the scan that determines bone density and candidacy, see What Is a CBCT Scan, and Why Does It Matter for Implants?

Can You Get All-on-4 on Osteoporosis Medication?

Usually, yes. Standard oral osteoporosis medication carries an MRONJ risk of roughly 0.001 to 0.01%, compared with 1 to 10% for cancer-dose IV bisphosphonates or denosumab, a difference of roughly 100 to 1,000 times (ADA, citing AAOMS 2022 position update).

MRONJ Risk by Bisphosphonate Type Horizontal bar chart on a square-root scale for readability given the large range. Oral osteoporosis-dose bisphosphonates: 0.001 to 0.01 percent MRONJ risk. IV oncologic-dose bisphosphonates or denosumab: 1 to 10 percent MRONJ risk, roughly 100 to 1,000 times higher. Source: ADA, citing AAOMS 2022 position update. Oral (osteoporosis dose) 0.001-0.01% IV (oncologic dose) 1-10% Square-root scale for readability; roughly 100-1,000x difference Source: ADA, citing AAOMS 2022 position update
Standard osteoporosis medication carries dramatically lower MRONJ risk than cancer-dose IV bisphosphonates (ADA/AAOMS, 2022).

[UNIQUE INSIGHT] Neither the ADA nor the AAOMS considers standard antiresorptive therapy for osteoporosis a contraindication for implants. This is a dose-stratified relative risk, not an absolute one, a distinction almost no patient-facing content makes clearly. Oncologic-dose IV therapy carries meaningfully higher risk and warrants direct discussion with your prescribing physician before treatment.

What Other Health Factors Actually Matter?

Radiation therapy history is no longer an absolute contraindication. Doses under 45 Gy show no added failure association, while doses over 60 to 66 Gy carry meaningfully higher risk (PMC10742198). Autoimmune conditions showed an overall implant survival of 88.75% at 24-plus months across a meta-analysis of 1,751 implants (International Journal of Implant Dentistry, 2019/2020).

A Sjögren’s syndrome case series found 100% survival over 4 to 13 years, and corticosteroid use alone wasn’t isolated as an independent negative factor in the pooled data. Generally reassuring, though still case-dependent, worth a direct conversation about your specific condition rather than a blanket assumption either way.

[PERSONAL EXPERIENCE] When evaluating an older or medically complex patient, we check systemic health markers and bone volume directly rather than assuming based on age or a diagnosis on paper. The chart, not the calendar, decides candidacy.

What If I Don’t Have Enough Bone?

Zygomatic implants, anchored in the cheekbone rather than the jaw, offer a well-documented alternative when bone volume is insufficient, with 96.2% survival at 6 years in a meta-analysis of 1,349 implants, comparable to conventional full-arch implants (PMC10322814, International Journal of Implant Dentistry, 2023).

Zygomatic vs. Conventional Full-Arch Implant Survival Lollipop chart. Zygomatic implants: 96.2 percent survival at 6 years. Conventional full-arch implants: 95.8 to 96.5 percent survival at 78 months, a comparable range. Source: PMC10322814, International Journal of Implant Dentistry, 2023, meta-analysis of 1,349 zygomatic implants. Zygomatic implants (6yr) 96.2% Conventional (low, 78mo) 95.8% Conventional (high, 78mo) 96.5% Source: PMC10322814, 2023 (1,349 zygomatic implants, 623 patients)
Zygomatic implants show survival comparable to conventional full-arch implants, a genuine alternative rather than a lesser fallback (PMC10322814, 2023).

Immediate loading actually outperformed delayed loading for zygomatic implants specifically, 98.1% versus 95%, p=0.03, a genuinely counterintuitive finding worth knowing. Sinusitis affects roughly 14% of zygomatic implant patients, a real tradeoff worth discussing directly rather than glossing over.

[ORIGINAL DATA] We’re building toward tracking our own candidacy-to-outcome data by age band and health factor, once case volume supports it, rather than relying only on published cohorts indefinitely.

Frequently Asked Questions

Is there an age limit for All-on-4 dental implants?

No sourced upper age limit exists. A 2025 meta-analysis found higher 5-year survival in patients over 75 (96.8%) than in the 65-75 group (92.1%), systemic health matters more than age itself.

What happens if I don’t have enough jawbone for All-on-4?

Zygomatic implants, anchored in the cheekbone, offer a well-documented alternative with 96.2% survival at 6 years, comparable to conventional full-arch implants.

Can I get All-on-4 if I’m on osteoporosis medication?

Usually, yes. Standard oral osteoporosis medication is not considered a contraindication, MRONJ risk is roughly 100 to 1,000 times lower than with cancer-dose IV bisphosphonates.

Can diabetics get All-on-4 implants?

Often, yes, particularly with well-controlled blood sugar. Discuss your specific glycemic control with your surgeon during candidacy assessment.

Does radiation therapy history rule out implants?

Not automatically. Doses under 45 Gy show no added failure risk, while doses over 60 to 66 Gy carry meaningfully higher risk, this is dose-dependent, not an automatic disqualifier.

Are zygomatic implants as reliable as standard All-on-4?

Survival data is comparable, 96.2% at 6 years for zygomatic versus 95.8 to 96.5% for conventional full-arch implants, though zygomatic implants carry a roughly 14% sinusitis rate worth discussing.

Conclusion

Candidacy comes down to systemic health and a proper CBCT-based bone assessment, not age or assumptions about “not enough bone,” both of which have real alternative pathways or reassuring data behind them.

Don’t self-disqualify based on age or a general health condition. A CBCT-based consultation is the only way to know for certain. For the complete full-arch guide, see All-on-4 and All-on-6 Dental Implants in Dubai.

Sources